Figure 5: Suppression of ERRα and glutamine sensitize cells to lapatinib.
From: ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
(a) Normalized cell index curves representing proliferation in pSKBr3 (left panel) and LRSKBr3 (right panel) cells on treatment with lapatinib and in presence or absence of the ERRα inhibitor C29 treatment. (b) Migration curves in pSKBr3 (left panel) and LRSKBr3 (right panel) cells on lapatinib and C29 treatment. (c) Normalized cell index curves representing proliferation in pSKBr3 (left panel) and LRSKBr3 (right panel) cells on depletion of L-glutamine from the growth media in presence or absence of the ERRα inhibitor C29. (d) Normalized cell index curves representing the survival of parental (left panel) and lapatinib-resistant (right panel) SKBr3 cells on increasing doses of lapatinib treatment. All error bars are s.d. from three independent experiments, statistical significance is calculated with a two-tailed unpaired t-test; *P<0.05; **P<0.01; ***P<0.001.
